Discovers and develops antibody-based treatments for infectious diseases. Focuses on solutions for use in the United States. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 9.5× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $53.4M a year. A small number, but proof the product has real buyers.
There is $226.7M in the vault; even if every debt were paid off, $224.2M would remain.
Over the last 12 months, company executives reported 21 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $52.5M against $53.4M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, the revenue breakdown.